Speaker: Komal Jhaveri, USA
#ESMOBreast24: Breaking Science in Breast Cancer Video Series
Safety of assisted fertility after breast cancer in young BRCA carriers
Abstracts discussed:
- 182MO - Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician’s Choice in HER2+ mBC: Watch the presentation from ESMO Breast 2024 now
- LBA2: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01: View the abstract from ESMO Breast 2024
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published July 2024